ABN AMRO Investment Solutions’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

ABN AMRO Investment Solutions’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,281	Closed	-$245K	–	427
2023 Q1	$245K	Buy	+2,281	New	+$263K	0.01%	388

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

ABN AMRO Investment Solutions's RXDX Position: Q2 2023 in Review

ABN AMRO Investment Solutions sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,281 shares — an estimated $245K sold.

ABN AMRO Investment Solutions first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $245K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

ABN AMRO Investment Solutions reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
ABN AMRO Investment Solutions sold 2,281 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $245K.
ABN AMRO Investment Solutions first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
ABN AMRO Investment Solutions's Prometheus Biosciences, Inc. Common Stock position peaked at $245K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on ABN AMRO Investment Solutions's 13F filing for Q2 2023, filed 5 Sep 2025.